Breaking News Headlines Today | Ground News

Black Friday Sale - Get 40% off Vantage

Eyewire+ image

News from Eyewire+

Eyewire+’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Eyewire+’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Eyewire+

Where is Eyewire+ located?Eyewire+'s Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Eyewire+ News

Ripple Therapeutics Enters Collaboration With Bausch + Lomb

Ripple Therapeutics Enters Collaboration With Bausch + Lomb

Ripple Therapeutics, a clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants, announced earlier this year that it entered into an evaluation program and licensing option agreement with an affiliate of Bausch + Lomb. Ripple’s patented technology platform is based on a discovery that drugs can be chemically engineered into controlled release pharmaceuticals without the use of polymers, wh…See the Story

Chester County, Pennsylvania · Chester County

Ocugen CEO to Spotlight Gene Therapy Breakthroughs at High-Profile Growth Conference

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) will present its latest advances in gene therapy for blindness diseases at NobleCon21, the annual emerging growth equity conference hosted by Noble Capital Markets, the company announced. Dr. Shankar Musunuri, Ocugen’s chairman, CEO and co-founder, is scheduled to deliver a presentation and fireside chat at 1 p.m. ET on Dec. 3 in Presentation Room 2 at Florida Atlantic University’s Executive Education Co…See the Story

Enrolment Concludes for Inflammasome’s K8 Phase II Trial for GA

Technology · United States

Enrolment Concludes for Inflammasome’s K8 Phase II Trial for GA

Inflammasome Therapeutics has completed subject enrolment for its multicentre Phase II trial of K8, a dual inflammasome inhibitor, aimed at treating geographic atrophy (GA).The post Enrolment concludes for Inflammasome’s K8 Phase II trial for GA appeared first on Clinical Trials Arena.See the Story

Breaking News Topics Related to Eyewire+